Medicago: A history of innovation and perseverance

Medicago believes in the power of plants to help protect public health.  Our journey started in 1999 with one objective: to help protect human life and today, we are a global leader in developing and producing plant-based vaccines and therapeutics. Our plant-based technology allows us to swiftly develop vaccines and therapies that can respond to pandemic situations and endemic diseases.

Our platform develops both vaccine and antibody candidates and is one of the few in the world with this capability. As Medicago continues with the research and development of vaccine candidates to help protect human health against viruses, we seek to expand our scope beyond viral diseases.

Our teams are working to develop vaccines, antibodies and therapeutic proteins that can be used, among other things, to fight infectious diseases and cancers. Medicago’s vaccine production platform is also capable of producing monoclonal antibodies artificially produced to treat a disease.

At Medicago, we’re proud of our humble beginnings as well as our evolution from an R&D company to bringing our first commercial products to market. We are growing our global capabilities but our roots in Quebec and Canada will always remain. Medicago has been a privately-held company since 2013.

Luzerne / Alfalfa

Medicago

Our company’s name was derived from the Latin name for alfalfa. This refers to the first plant with which we worked and always reminds us of our adaptable nature.

Medicago through time

  • 1997

    R&D

    Research partnership between Laval University and Agriculture Canada

  • 1999

    Corporate

    Medicago was incorporated to leverage the technology licensed from Laval University and Agriculture Canada

  • 2005

    R&D

    Development of new transient expression technologies with Nicotiana benthamiana

  • 2009

    Production

    Production of an H1N1 pandemic candidate VLP vaccine 19 days after publication of the virus genetic sequence

  • 2011

    Corporate

    Manufacturing plant built in Durham NC with the creation of Medicago USA

  • 2012

    Production

    Production of more than 10M doses of H1N1 VLP vaccine in one month through partnership with U.S. DARPA.

  • 2015

    R&D

    Production of an anti-Ebola monoclonal antibody formula for the U.S. Biomedical Advanced Research and Development Authority (BARDA).

  • 2015

    R&D

    Production of Ebola virus antibodies for the Sudan Strain through partnership with the Public Health Agency of Canada

  • 2018

    Corporate

    Integrated manufacturing facility built in Quebec City

  • 2020

    Production

    Production of a COVID-19 candidate VLP vaccine was announced to offer an effective response to the pandemic.